KR930017881A - 술폰아미드 엔도텔린 길항제 - Google Patents

술폰아미드 엔도텔린 길항제 Download PDF

Info

Publication number
KR930017881A
KR930017881A KR1019930002492A KR930002492A KR930017881A KR 930017881 A KR930017881 A KR 930017881A KR 1019930002492 A KR1019930002492 A KR 1019930002492A KR 930002492 A KR930002492 A KR 930002492A KR 930017881 A KR930017881 A KR 930017881A
Authority
KR
South Korea
Prior art keywords
isoxazolyl
dimethyl
naphthalenesulfonamide
amino
alkyl
Prior art date
Application number
KR1019930002492A
Other languages
English (en)
Other versions
KR100257134B1 (ko
Inventor
디. 스테인 필립
티. 헌트 존
무루게산 나테산
Original Assignee
니콜라스 피. 말라테스티닉
이이.아르.스퀴브 앤드 산즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니콜라스 피. 말라테스티닉, 이이.아르.스퀴브 앤드 산즈, 인크. filed Critical 니콜라스 피. 말라테스티닉
Publication of KR930017881A publication Critical patent/KR930017881A/ko
Application granted granted Critical
Publication of KR100257134B1 publication Critical patent/KR100257134B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Optical Fibers, Optical Fiber Cores, And Optical Fiber Bundles (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Glass Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Indole Compounds (AREA)

Abstract

본 발명은 엔도텔린을 억제하는 하기 일반식의 화합물에 관한 것이다.
상기 식에서, X및 Y중의 하나는 N이고, 다른 하나는 O이고, R은 나프틸 또는 R1,R2및 R3으로 치환된 나프틸이고, R1,R2및 R3은 각각 독립적으로 수소, Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬, 할로, 히드록실, 시아노, 니트로, -C(O)H,-C(O)R6,CO2H,-CO2R6,-SH,-S(O)nR6,-S(O)m-OH,-S(O)m-OR6,-O-S(O)m-R6,-O-S(O)mOH,-O-S-(O)-m-OR6,-Z4-NR7R8,또는 -Z4-N(R11)-Z5-NR9R10이고, R4및 R5는 각각 독립적으로 수소, Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬, 할로, 히드록실, 시아노, 니트로, -C(O)H,-C(O)R6,CO2H,-CO2R6,-SH,-S(O)nR6,-S(O)m-OH,-S(O)m-OR6,-O-S(O)m-R6,-O-S(O)mOH,-O-S-(O)-m-OR6,-Z4-NR7R8,또는 -Z4-N(R11)-Z5-NR9R10이거나, 또는 R4및R5는 함께 그들이 결합된 탄소 원자와 함께 4내지 8원 포화, 불포화, 또는 방향족 고리를 완성하고, Z1,Z2및 Z3으로 치환될 수 있는, 알킬렌 또는 알케닐렌이고, 여기에서, R6,R7,R8,R9,R10,R11,Z6,Z7,Z9, m및 n은 상기 정의한 바와 같다.

Description

술폰아미드 엔도텔린 길항제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (20)

  1. 하기 일반식의 화합물 또는 제약상 허용되는 그의 염.
    상기 식에서, X및 Y중의 하나는 N이고, 다른 하나는 O이고, R은 나프틸 또는 R1,R2및 R3으로 치환된 나프틸이고, R1,R2및 R3은 각각 독립적으로, (a)수소, (b)Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬, (c)할로, (d)히드록실, (e)시아노, (f)니트로, (g)-C(O)H또는-C(O)R6, (h)CO2H,-CO2R|6,(i)-SH,-S(O)n-R6,-S(O)m-OH,-S(O)m-R6,-O-S(O)m-R|6,-S(O)mOH또는-S-(O)m-OR6,-Z4-NR7R|8,또는 (k)-Z4-N(R11)-Z5-NR9R10이고, R4및 R5는 각각 독립적으로 (a)수소, (b)Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬, (c)할로, (d)히드록실, (e)시아노, (f)니트로, (g)-C(O)H 또는-C(O)R6,(h)CO2H또는-CO2R6,(i)-SH,-S(O)|n-R6,-S(O)m-OH,-S(O)m-OR6,-O-S(O)m-R6,-O-S(O)mOH 또는-S(O)|m-OR6,(j)-Z4-NR7R8또는 (k)-Z4-N(R11)-Z5-NR9R10이거나, 또는 (1)R4및R5는 함께 그들이 결합된 탄소 원자와 함께 4내지 8원 포화, 불포화, 또는 방향족 고리를 완성하는 Z1,Z2및 Z3으로 치환될 수 있는 알킬렌 또는 알케닐렌이고, R6은Z1,Z2및Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴, 또는 아랄킬이고, R7은, (a)수소, (b)Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬, (c)시아노, (d)히드록실, (e)-C(O)H 또는-C(O)R6,(f)CO2H또는-CO2R6,또는(g)-SH,-S(O)nR6,-S(O)m-OH,-S(O)m-OR6,-O-S(O)m-R6,-O-S(O)mOH 또는-0-S(O)m-OR6이고,(단,Z4가 -S(0)m-인 경우는 제외함),R8은, (a)수소, (b)-C(O)H 또는C(O)R6(단, Z4가 -C(O)-이고, R7이 -C(O)H, -C(O)R6,-CO|2H 또는 -CO2R6인 경우는 제외함),또는 (c) Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬이거나, 또는 R7및R8은 함께 그들이 결합된 질소 원자와 함께 3내지 8원 포화, 불포화 또는 방향족 고리를 완성하는 Z1,Z2및 Z3으로 치환될 수 있는 알킬렌 또는 알케닐렌이고, R9는, (a)수소, (b)히드록실, (c)-C(O)H 또는-C(O)R6,(d)-CO2H또는-CO2R6,(e)-SH,-S(O)n-R6,-S(O)m-OH,-S(O)m-OR|6,-O-S(O)m-R6,-O-S(O)mOH 또는-S(O)m-OR6,
    또는 (f) Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬이고,R10은, (a)수소,(b)-C(O)H 또는 -C(O)R6(단, Z5가 -C(O)-이고, R9가-C(O)H,-C(O)R|6,-CO2H 또는 CO2R6인 경우는 제외함),또는 (c)Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬이고,R11은, (a)수소,(b)히드록실, -CO2R6또는 CO|2H(단, R9및R10중의 하나가 히드록실, CO2R6또는CO2H인 경우는 제외함),(c) -C(O)H 또는-C(O)R6,또는 (d) Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 알콕시, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬이거나, R9,R10및 R11중의 임의의 2개는 함께 그들이 결합된 원자들과 함께 3내지 8원 포화, 불포화 또는 방향족 고리를 완성하는, Z1,Z2및 Z3으로 치환될 수 있는 알킬렌 또는 알케닐렌이고, Z1,Z2및 Z3은 각각 독립적으로, (a)수소,(b)할로, (c)히드록시, (d)알콕시, (e)-SH, -S(O)nZ6,-S(O)m-OH,-S(O)m-OZ6,-O-S(O)|m-Z6,-O-S(O)mOH또는-S(O)m-OZ6,(f)옥소,(g)니트로,(h)시아노,(i)-C(O)H 또는 -C(O)Z6,(j)-CO|2H또는CO2Z6, 또는(k)-NZ7Z8,-C(O)NZ7Z8또는-S(O)nZ7Z|8이고, Z4및Z5는 각각 독립적으로, (a)단일결합, (b)-S(O)n-,(c)-C(O)-,(d)-C(S)또는(e)Z1,Z2및 Z3으로 치환될 수 있는, 알킬, 알케닐, 알키닐, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬이고,Z6,Z7및 Z8은 각각 독립적으로 수소,알킬, 알케닐, 알키닐, 시클로알킬, 시클로알킬알킬, 시클로알케닐, 시클로알케닐알킬, 아릴 또는 아랄킬이거나, 또는 Z7및 Z8은 함께 그들이 결합된 질소 원자와 함께 3내지 8원 포호, 불포화 도는 방향족 고리를 완성하는 알킬렌 또는 알케닐이고, m은 1또는 2이고,n은 0,1또는 2이다.
  2. 제1항에 있어서, R1,R2및 R3중의 하나가 -NR7R8인 화합물,
  3. 제2항에 있어서, R7및 R8이 각각 독립적으로 수소, 알킬, 또는 C(O)알킬인 화합물.
  4. 제1항에 있어서, R이이고, 여기에서, 1또는 2위치에는 술폰아미드가 결합되고, 5또는 6위치에는 R1,R2및 R3중의 하나가 결합된 화합물.
  5. 제4항에 있어서, R1,R2및 R3중의 하나가 -NR6R8인 화합물.
  6. 제5항에 있어서, R7및 R8이 각각 독립적으로 수소,알킬 또는 C(O)알킬인 화합물.
  7. 제6항에 있어서, R7및 R8이 각각 독립적으로 수소, 메틸, 메틸에틸 또는 아세틸인 화합물.
  8. 제1항에 있어서, 하기 식을 갖는 화합물.
  9. 제8항에 있어서, R7및 R8이 각각 독립적으로 수소,알킬 또는 C(O)알킬인 화합물.
  10. 제9항에 있어서, R7및 R8이 각각 독립적으로 수소, 메틸, 메틸에틸 또는 아세틸인 화합물.
  11. 제1항에 있어서, R4및 R5가 알킬인 화합물.
  12. 제4항에 있어서, R4및 R5가 알킬인 화합물.
  13. 제1항에 있어서, R4및 R5가 메틸인 화합물.
  14. 제4항에 있어서, R4및 R5가 메틸인 화합물.
  15. 제1항에 있어서, 5-(디메틸아미노)-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,N-[5-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-1-나프탈레닐]아세트아미드, 5-아미노-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,N-[6-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-1-나프탈레닐]아세트아미드,5-아미노-N-(3,4-디메틸-5-이속사졸릴)-2-나프탈렌술폰아미드,N-[4-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-1-나프탈레닐]아세트아미드,N-[6-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-2-나프탈레닐]아세트아미드,6-아미노-N-(3,4-디메틸-5-이속사졸릴)-2-나프탈렌술폰아미드,4-아미노-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,5-디메틸아미노-N-(4,5-디메틸-3-이속사졸릴)-1-나프탈렌술폰아미드,N-[5-[[(4,5-디메틸-3-이속사졸릴)아미노]술포닐]-1-나프탈레닐]아세트아미드,N-[5-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-2-나프탈레닐]아세트아미드,N-[8-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-2-나프탈레닐]아세트아미드,N-[7-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-2-나프탈레닐]아세트아미드,N-[7-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-1-나프탈레닐]아세트아미드,N-(3,4-디메틸-5-이속사졸릴)-5-메톡시-1-나프탈렌술폰아미드,N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,5-[(1-메틸에틸)아미노]-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,N-[5-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-1-나프탈레닐]-2-메틸프로판아미드,5-클로로-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,N-(3,4-디메틸-5-이속사졸릴)-5-[(페닐메틸)아미노]-1-나프탈렌술폰아미드,N-(3,4-디메틸-5-이속사졸릴)-5-히드록시-1-나프탈렌술폰아미드,7-(디메틸아미노)-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,N-(3,4-디메틸-5-이속사졸릴)-5-[메틸(1-메틸에틸)-아미노]-1-나프탈렌술폰아미드,2-[[5-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-1-나프탈레닐]아미노]프로판산, 에틸 에스테르, N-(3,4-디메틸-5-이속사졸릴-5-(2-옥소-1-피롤리디닐)-1-나프탈렌술폰아미드,N-(3,4-디메틸-5-이속사졸릴)-5-(2-옥소-1-피페리디닐)-1-나프탈렌술폰아미드,N-(3,4-디메틸-5-이속사졸릴)-5-[[(페닐아미노)-티옥소메틸]아미노]-1-나프탈렌술폰아미드,N-(3,4-디메틸-5-이속사졸릴)-5-(1-피롤리디닐)-1-나프탈렌술폰아미드,5-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-1-나프탈렌카르복실산,5-[[[5-(디메틸아미노)-1-나프탈레닐]술포닐]아미노]-3-메틸-4-이속사졸카르복실산,에틸 에스테르,5-[[(3,4-디메틸-5-이속사졸릴)아미노]술포닐]-1-나프탈렌카르복실산,메틸 에스테르,5-(디메틸아미노)-N-(3-메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,5-[(디메틸아미노)메틸]-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,트리플루오로아세테이트(1:1)염,N-(3,4-디메틸-5-이속사졸릴)-5-(1-히드록시-1-메틸에틸)-1-나프탈렌술폰아미드,N-(3,4-디메틸-5-이속사졸릴)-5-(1-메틸에테닐)-1-나프탈렌술폰아미드, N-(3,4,-디메틸-5-이속사졸릴-5-(1-피페리디닐)-1-나프탈렌술폰아미드.트리플루오로아세테이트(2;1) 염, N-(3,4-디메틸-5-이속사졸릴)-5-(메틸아미노)-1-나프탈렌술폰아디므, N-(3,4-디메틸-5-이속사졸릴)-5-(에틸아미노)-1-나프탈렌술폰아미드, N-(3-메틸-4-페닐메틸-5-이속사졸릴)-5-[디메틸아미노]-1-나프탈렌술폰아미드, N-(3-메틸-4-페닐-5-이속사졸릴)-5-(디메틸아미노)-1-나프탈렌술폰아미드,N-(3-에틸-4-메틸-5-이속사졸릴)-5-(디메틸아미노)-1나프탈렌술폰아미드,5-(디부틸아미노)-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,일나트륨염, 4-[1-[[(3,4-디메틸-5-이속사졸릴]아미노]술포닐]나프탈렌-5-일]아미노]부탄산, 6-아미노-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,7-아미노-N-(3,4-디메틸-5-이속사졸릴)-2-나프탈렌술폰아미드,8-아미노-N-(3,4-디메틸-5-이속사졸릴)-2-나프탈렌술폰아미드,7-아미노-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,7-(디메틸아미노)-N-(3,4-디메틸-5-이속사졸릴)-2-나프탈렌술폰아미드,8-(디메틸아미노-N-(3,4-디메틸-5-이속사졸릴)-2-나프탈렌술폰아미드,6-(디메틸아미노)-N-(3,4-디메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,5-(디메틸아미노)-N-(3-메틸-4-니트로-5-이속사졸릴)-1-나프탈렌술폰아미드,5-(디메틸아미노)-N-(4,5,6,7-테트라히드로-2,1-벤즈이속사졸릴-3-일)-1-나프탈렌술폰아미드,5-(디메틸아미노)-N-(4-에틸-3-메틸-5-이속사졸릴)-1-나프탈렌술폰아미드,및 5-(디메틸아니노)-N-(4-메틸-5-이속사졸릴)-1-나프탈렌술폰아미드로 이루어진 군 중에서 선택된 화합물.
  16. 유효량의 제1항에 따른 화합물을 투여하는 것으로 이루어진 포유류에 있어서 엔도텔린 관련 질환을 치료하는 방법.
  17. 유효량의 제1항에 따른 화합물을 투여하는 것으로 이루어진 고혈압을 치료하는 방법.
  18. 유효량의 제1항에 따른 화합물을 투여하는 것으로 이루어진 신장, 시구체 또는 사구체 간질 세포 관련 질환을 치료하는 방법.
  19. 유효량의 제1항에 따른 화합물을 투여하는 것으로 이루어진 내독소혈병을 치료하는 방법.
  20. 유효량의 제1항에 따른 화합물을 투여하는 것으로 이루어진 빈혈을 치료하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930002492A 1992-02-24 1993-02-23 술폰아미드 엔도텔린 길항제 KR100257134B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84049692A 1992-02-24 1992-02-24
US07/840,496 1992-02-24
US7/840,496 1992-02-24

Publications (2)

Publication Number Publication Date
KR930017881A true KR930017881A (ko) 1993-09-20
KR100257134B1 KR100257134B1 (ko) 2000-05-15

Family

ID=25282528

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930002492A KR100257134B1 (ko) 1992-02-24 1993-02-23 술폰아미드 엔도텔린 길항제

Country Status (26)

Country Link
EP (1) EP0558258B1 (ko)
JP (1) JP3273818B2 (ko)
KR (1) KR100257134B1 (ko)
CN (1) CN1044235C (ko)
AT (1) ATE152713T1 (ko)
AU (1) AU651922B2 (ko)
CA (1) CA2089184A1 (ko)
CY (1) CY2045B1 (ko)
DE (1) DE69310414T2 (ko)
DK (1) DK0558258T3 (ko)
EG (1) EG20143A (ko)
ES (1) ES2103061T3 (ko)
FI (1) FI930774A (ko)
GR (1) GR3024203T3 (ko)
HK (1) HK121597A (ko)
HU (1) HU219455B (ko)
IL (1) IL104748A (ko)
MX (1) MX9300842A (ko)
MY (1) MY109004A (ko)
NO (1) NO303012B1 (ko)
NZ (1) NZ245905A (ko)
PH (1) PH30795A (ko)
PL (1) PL172035B1 (ko)
RU (1) RU2116301C1 (ko)
TW (1) TW224462B (ko)
ZA (1) ZA93780B (ko)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
CA2121724A1 (en) 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5391566A (en) * 1993-07-20 1995-02-21 Merck & Co., Inc. Benzimidazolinones substituted with phenoxyphenylacetic acid derivatives
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
ES2081251B1 (es) * 1993-08-04 1996-10-16 Squibb & Sons Inc Antagonistas de endotelina, a base de sulfonamida.
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5780498A (en) * 1993-11-01 1998-07-14 Ciba-Geigy Japan Limited Endothelin receptor antagonists
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
ES2201181T3 (es) * 1995-04-04 2004-03-16 Encysive Pharmaceuticals Inc. Tienil-, furil-, pirrolil- y bifenilsulfonamidas y derivados de los mismos que modulan la actividad de endotelina.
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
SG87051A1 (en) 1996-02-20 2002-03-19 Bristol Myers Squibb Co Process for preparing biphenyl isoxazole sulfonamide intermediates
US5958905A (en) * 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US5783705A (en) * 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
IL131318A (en) 1997-04-28 2004-08-31 Encysive Pharmaceuticals Inc Pharmaceutically acceptable salts of sulfonamides for treatment of endothelin-mediated disorders
JP3783411B2 (ja) 1997-08-15 2006-06-07 富士ゼロックス株式会社 表面発光型半導体レーザ
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
IL144708A0 (en) 1999-03-19 2002-06-30 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamide derivatives
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
KR20020072285A (ko) 1999-12-31 2002-09-14 텍사스 바이오테크놀로지 코포레이션 엔도텔린의 활성을 조절하는 설폰아미드 및 이의 유도체
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
JP4293734B2 (ja) * 2001-01-17 2009-07-08 三菱電機株式会社 電動式パワーステアリング制御装置
JP4448902B2 (ja) 2001-06-08 2010-04-14 株式会社医薬分子設計研究所 スルホンアミド誘導体
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
DE10256186A1 (de) * 2002-12-02 2004-06-09 Bayer Ag Cyclopenta(c)isoxazol-3-amine als Materialschutzmittel
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
BRPI0517263A (pt) * 2004-10-29 2008-10-07 Astrazeneca Ab novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
JP5204662B2 (ja) 2005-11-22 2013-06-05 アムジエン・インコーポレーテツド １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤
WO2008011453A2 (en) 2006-07-20 2008-01-24 Amgen Inc. SUBSTITUTED AZOLE AROMATIC HETEROCYCLES AS INHIBITORS OF LLβ-HSD-1
JP4518065B2 (ja) * 2006-10-25 2010-08-04 宇部興産株式会社 新規ジアルコキシアミドオキシム誘導体及びその製法
JP4518066B2 (ja) * 2006-10-25 2010-08-04 宇部興産株式会社 ジアルコキシニトリル誘導体及びその製法
TW200829578A (en) 2006-11-23 2008-07-16 Astrazeneca Ab Chemical compounds 537
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
US8211930B2 (en) 2008-05-20 2012-07-03 Astrazeneca Ab Phenyl and benzodioxinyl substituted indazoles derivatives
CN101818056B (zh) * 2010-05-27 2013-07-31 中南大学 一类丹磺酰类分子探针及其合成方法和应用
JP6144631B2 (ja) * 2012-01-31 2017-06-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 シタキセンタン誘導体
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
RS64931B1 (sr) 2019-06-18 2023-12-29 Pfizer Derivati benzizoxazol sulfonamida

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2888455A (en) * 1956-09-04 1959-05-26 Shionogi & Co New sulfonamide and process for producing the same
US3300488A (en) * 1963-12-23 1967-01-24 Shionogi & Co Nu, nu'-bis [4-halogenated-5-alkyl-3-isoxazolylsulfamoyl)-phenyl]-ureas
GB1473433A (ko) * 1975-10-09 1977-05-11 Banyu Pharmaceutical Co Ltd Hi
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
TW270116B (ko) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина

Also Published As

Publication number Publication date
FI930774A (fi) 1993-08-25
IL104748A0 (en) 1993-06-10
HK121597A (en) 1997-09-12
HU9300491D0 (en) 1993-05-28
JPH069585A (ja) 1994-01-18
DE69310414D1 (de) 1997-06-12
DK0558258T3 (da) 1997-05-26
NZ245905A (en) 1995-07-26
MX9300842A (es) 1993-08-01
HUT65762A (en) 1994-07-28
JP3273818B2 (ja) 2002-04-15
PH30795A (en) 1997-10-17
EG20143A (en) 1997-07-31
CY2045B1 (en) 1998-04-30
EP0558258B1 (en) 1997-05-07
NO930633D0 (no) 1993-02-23
CN1079468A (zh) 1993-12-15
GR3024203T3 (en) 1997-10-31
ATE152713T1 (de) 1997-05-15
NO930633L (no) 1993-08-25
CA2089184A1 (en) 1993-08-25
FI930774A0 (fi) 1993-02-22
KR100257134B1 (ko) 2000-05-15
MY109004A (en) 1996-11-30
HU219455B (hu) 2001-04-28
RU2116301C1 (ru) 1998-07-27
AU651922B2 (en) 1994-08-04
ES2103061T3 (es) 1997-08-16
ZA93780B (en) 1993-09-08
PL297820A1 (en) 1993-09-06
EP0558258A1 (en) 1993-09-01
AU3319293A (en) 1993-08-26
PL172035B1 (pl) 1997-07-31
TW224462B (ko) 1994-06-01
DE69310414T2 (de) 1997-12-11
CN1044235C (zh) 1999-07-21
IL104748A (en) 1996-10-16
NO303012B1 (no) 1998-05-18

Similar Documents

Publication Publication Date Title
KR930017881A (ko) 술폰아미드 엔도텔린 길항제
KR930023337A (ko) 페닐 술폰아미드 엔도텔린 길항물질
RU2397171C2 (ru) 9-замещенное производное 8-оксоаденина и лекарственное средство
KR930700490A (ko) 탄산탈수효소 억제제로서 유용한 티오펜 설폰아미드
RU2007102281A (ru) 5-аза-7-деазапуриновые производные для лечения заболеваний, связанных с flaviviridae
KR900003151A (ko) 화합물
JP2004518767A5 (ko)
KR890012649A (ko) 아릴아미도(및 아릴티오아미도)-아자비사이클로 알칸으로 기억력을 향상시키거나 기억력 부족을 교정시키는 방법
HK1069986A1 (en) Topical application of thiazolyl amides
KR950005811A (ko) 술폰아미드 엔도세린 길항제
KR930000453A (ko) 아릴에테르, 이의 제조방법 및 이를 이용하는 치료방법
FI80877B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara spiro/4,(3+n)/-2-azaalkan-3-karboxylsyraderivat och vid framstaellning av dessa anvaendbara foerening.
FI915970A0 (fi) Laekemedel, som aer nyttiga vid vaord av cancer och som har antihistaminegenskaper.
KR930021637A (ko) 1,2,4-옥사디아졸릴-페녹시알킬이소옥사졸 및 항바이러스제로서의 그의 용도
FI913833A0 (fi) Ringsubstituerade 2-amino -1,2,3,4-tetrahydronaftalener, 3-aminokromaner och 3-aminotiokromaner.
ES2149777T3 (es) Derivados de triazol que tienen actividad antifungica.
DK0629635T3 (da) Hidtil ukendte 19-nor-11beta-phenoxysulfonamid- eller 11beta-phenoxysulfonylureasteroider, fremgangsmåde og mellemprodukter til deres fremstilling, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
JP2003012668A5 (ko)
JP2004524345A5 (ko)
RU2225393C1 (ru) Новые производные аминоциклогексана
RU2005119172A (ru) Производные 4-анилинхиназолина для лечения патологического роста клеток
CA2442870A1 (en) Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
KR950032194A (ko) 신규푸린유도체 및 그 약학적으로 허용되는 염
CA2479012A1 (en) Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
KR930021203A (ko) 죽상동맥경화 치료제로서의 독사조신의 히드록실화된 대사산물 및 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030224

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee